Renalytix Plc (RNLX)

0.6020 -0.0221 (-3.54%) As of 12:18PM EDT. Market open.

Renalytix Plc

1460 Broadway
New York, NY 10036
United States
646 397 3970
https://renalytix.com

Sector(s): Healthcare
Industry: Health Information Services
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. James R. McCullough M.B.A.	Chief Executive Officer	1.04M	N/A	1968
Mr. Thomas H. McLain CPA, M.B.A	President	662.7k	N/A	1959
Mr. Oliver James Sterling III	Chief Financial Officer	623.68k	N/A	N/A
Mr. Fergus Fleming	Chief Technology Officer	N/A	N/A	1968
Mr. Howard B. Doran Jr.	Chief Business Officer	N/A	N/A	1961
Mr. Salim Gulamabbas Hamir F.C.A.	Company Secretary	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.

Corporate governance

Renalytix Plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.